Send us a text

What do you need to know about the market access and reimbursement landscape in Canada? What changes can we expect at the Canadian Agency for Drugs and Technologies in Health (CADTH) in 2024/2025?  In this webinar, Clare Foy (Director – Global Market Access, Mtech Access) interviewed Don Husereau (Adjunct Professor of Medicine, The University of Ottawa).

We take a look at the market access, health policy, and health technology assessment in Canada. Clare Foy and Don Husereau explore:

• The market access landscape in Canada
• Upcoming changes at CADTH
• What Canadian payers expect from your value proposition
• Opportunities and challenges when launching new medicines/medical devices/diagnostics in Canada
• How Canada compares to the USA/key European launch markets
• What this means for your global market access strategy

This episode was first broadcast as a live webinar in March 2024. Learn more at https://mtechaccess.co.uk/market-access-canada-changes-cadth/


Learn more about the Canadian healthcare market and launching new pharma and medtech innovations at: https://mtechaccess.co.uk/launching-healthcare-products-in-canada/

Subscribe to our newsletter to hear more news, insights and events from Petauri Evidence

Send us a text

Where will you be launching your new orphan medicine? You may be confident that your Global market access strategy will support access in key launch markets like the UK, the EU4 and the US, but have you thought about other markets? Have you looked at the reimbursement requirements for rare disease products in the Nordic markets? Have you explored opportunities in growth markets, such as those in the Middle East and North Africa (MENA) region?

In this webinar,  our Global Market Access team compare and contrast access opportunities and challenges for rare disease treatments in the differing markets of the Nordic and MENA regions, asking: what does this mean for your overarching market access strategy?

Our Global Market Access experts explore contrasting regions to showcase the significant differences between international markets when it comes to:

 - Overall and rare disease patient populations
 - Access inequalities
 - Time to diagnosis
 - Access to innovation timelines
 - Healthcare funding
 - Health technology assessment frameworks

Robert Taaffe (Consultant – Global Market Access) presents his research into the market access conditions in the MENA regions, with a focus on the rare disease reimbursement landscape in growth markets in Egypt, Saudi Arabia, and the United Arab Emirates.

Michelle James (Associate Consultant – Global Market Access) showcases market access and reimbursement routes in the more established, yet smaller populations in the Nordic regions. Michelle will focus on access in Denmark, Sweden, and Norway.

Clare Foy (Director – Global Market Access) leads our discussion on the opportunities and challenges of launching in markets with different conditions and requirements, and how this should play into your overarching Global market access strategy.

Learn more at and request a copy of the webinar slides at: https://mtechaccess.co.uk/rare-disease-market-access-nordic-and-mena/

Discover how Mtech Access can support you with market access, pricing and reimbursement for rare disease treatments at: https://mtechaccess.co.uk/global-market-access-and-pricing/

Subscribe to our newsletter to hear more news, insights and events from Petauri Evidence

Send us a text

Which decisions are made at Region level in the NHS in England? How do finances and funding work at this level? And how can industry best support and engage with Region leaders?

We sit down with guest speaker Richard Smale (Interim Director of System Co-ordination, NHS England [NHSE] – South West) for an all-encompassing discussion that explored finance, funding flows, system priorities, and the decision-making process in NHS Regions.

Richard heads up system co-ordination work across the NHS South West Region. The Region has seven Integrated Care Boards (ICBs), 22 Trusts, nine counties and a resident population of over 5.5 million patients stretching from Gloucestershire and Wiltshire to the Isles of Scilly.

The interview was led by David Thorne (Principal Consultant, Mtech Access and Transformation Director at Well Up North Primary Care Network [PCN]) who put both the NHS and industry perspectives to Richard to explore the real state of the NHS.

In this episode, David and Richard discuss:
- Where the NHS is heading and what this means for your strategy and business planning
- Decision making, finances, and funding flows across the NHS
- The role of NHS Regions, particularly with key funding decisions like Specialised Commissioning
- Delivering service change across integrated systems
- Policy priorities in practice and what to expect in an election year
- How Pharma, Medtech, and Diagnostics companies can best engage NHS leaders at Region level

This episode was first broadcast as a live webinar in February 2024.
Learn more about the webinar and Richard at: https://mtechaccess.co.uk/how-does-funding-flow-in-nhse-regions/

Discover more about our NHS Insights services at: https://mtechaccess.co.uk/uk-nhs-insights/

Subscribe to our newsletter to hear more news, insights and events from Petauri Evidence

Send us a text

What do we know about plans and policy for 2024/25? As the expected central operating plan had not materialised (at time of recording), and with a general election and a potential Labour government on the horizon, how can NHS and industry drive forward improvements and innovation?

Host Robert Hull (Senior Consultant – NHS Insight & Interaction, Mtech Access) was joined by guest speakers Debbie Morgan (Director of Service Improvement and Transformation, Cambridge University Hospitals NHS Foundation Trust), Ellen Rule (Deputy CEO/Director of Strategy & Transformation, Gloucestershire Integrated Care Board) and Dr Viren Mehta (GP Partner, GP Federation Chief Officer, Viaduct Care). Together we explored what all this uncertainty means for NHS decision-making, day-to-day operations, strategy, and engagement with industry.

In this webinar, we bring together leaders from across the NHS to explore how they are planning and operating in this uncertainty.

We explore:
 - Strategy and planning in these times of uncertainty
 - What’s happening with GP contracts
 - Financial pressures and challenges
 - If/where it’s possible to drive forward change in the current environment
 - How Pharma and Medtech can best support NHS leaders
 - Where the panel would welcome solutions from industry

Please note this episode was first broadcast in January 2024 as a live webinar. Some aspects of policy discussed have evolved and continue to evolve.

Discover more at:  https://mtechaccess.co.uk/nhs-policy-for-2024-25/

Learn more about our NHS insights services at: https://mtechaccess.co.uk/uk-nhs-insights/

Subscribe to our newsletter to hear more news, insights and events from Petauri Evidence

Send us a text

What is health economic evaluation and which modelling approaches can be used to support market access activities?

In this episode, our expert health economists explain the key strengths and limitations of the most common health economic modelling classifications and structures. Here, Hannah Gillies (Consultant – Health Economics) and Daniel MacDonald (Associate Consultant – Health Economics) de-mystify the different approaches to health economic modelling.

Our specialists explore six of the most common health economic modelling structures used to support market access activities;
 - Decision trees
 - Markov models
 - Semi-Markov models
 - Partitioned survival models
 - Cox regression models
 - Discrete event simulations

This episode was first broadcast as a live webinar in January 2024. For more information or to request a copy of the slides used, please visit: https://mtechaccess.co.uk/de-mystifying-health-economic-models/

Work with our health economists:  https://mtechaccess.co.uk/health-economics/

Subscribe to our newsletter to hear more news, insights and events from Petauri Evidence

Send us a text

Here, our experts explore evidence strategies for medical devices, diagnostics and digital health technologies.

Have you established the clinical and economic value of your medical device, diagnostic or digital technology? Do you have the evidence required to support your value proposition? Would a health technology assessment (HTA) route be appropriate for your product? What will payers, HTA agencies, and other key decision makers be looking for? And how should this information be presented?

In this episode, our experts in HTA, health economics, and commercialisation explore:
- How to identify and communicate the value of your product for patients and the wider healthcare system
- How to build a robust evidence package for successful launch and commercialisation
- Key requirements for the National Institute for Health and Care Excellence (NICE) Medical Technologies Evaluation Programme (MTEP) or Diagnostics Assessment Programme (DAP)
- Next steps to take your innovation to healthcare leaders across the NHS and beyond, with an impactful customer communication strategy

This episode was first broadcast as a live webinar in January 2023. Learn more and request a copy of the slides at: https://mtechaccess.co.uk/evidence-strategy-for-medical-technologies-and-diagnostics/

Discover how Mtech Access can support your commercialisation journey at: https://mtechaccess.co.uk/medical-device-market-access/

Subscribe to our newsletter to hear more news, insights and events from Petauri Evidence

Send us a text

How can you ensure your product is set up for success from early clinical trials right through to launch and commercialisation? In this Global Whispers webinar we explore best practice commercialisation strategy for healthcare products launching in the US market.

Clare Foy (Director – Global Market Access, Mtech Access) speaks to Janice MacLennan (Pharma and Medtech brand strategist and founder of NMBLR) about how market access, HEOR and commercialisation leads in Pharma and Medtech can best support overarching product and brand strategy, with a focus on launch challenges in the US market.

We take a step back from the intricacies of market access and HEOR, to explore the role our specialism plays in broader commercial and product strategy. We ask: where does market access and HEOR sit in this broader picture, and how can market access teams best support their product and company brand?

Using the US market as our case study, we explore:

- How to set up your product for success
- Commercialisation routes in the US for Pharma and Medtech
- The relationship between brand strategy and market access
- What Pharma can learn from Medtech’s approach to commercialisation
- What Medtech innovators can learn from Pharma companies’ approach to launch

This episode was first broadcast as a live webinar in January 2024.

Learn more at: https://mtechaccess.co.uk/commercialisation-strategy-us-market/

Explore our work in the US market: https://mtechaccess.co.uk/launching-healthcare-products-in-the-us/

Discover how Mtech Access can support you global market access and pricing strategy: https://mtechaccess.co.uk/global-market-access-and-pricing/

Subscribe to our newsletter to hear more news, insights and events from Petauri Evidence

Send us a text

What’s happening with specialised commissioning in the NHS? How likely is a delay in delegation to integrated care boards (ICBs)? How and what should Pharma and Medtech plan for amidst all this uncertainty?

Malcolm Qualie (former Medicines Lead for Specialised Services, NHS England) speaks to David Thorne (Principal Associate, Mtech Access) to explore specialised commissioning in the NHS and what to expect as we head into 2024.

Malcolm Qualie and David Thorne explored:

• Specialised commissioning in the NHS
• The risks and opportunities that devolution to ICBs will bring
• What we can expect to see in the short and longer term
• How industry can support ICB leaders through this transition
• How Pharma, Medtech, and Diagnostics companies, whose products come under specialised commissioning, can manage these risks and uncertainties

Learn more at https://mtechaccess.co.uk/nhs-specialised-commissioning/

This episode first broadcast as a live webinar in Decmeber 2023. 

Subscribe to our newsletter to hear more news, insights and events from Petauri Evidence

Send us a text

What does it take to run a truly patient-centric integrated health system? What does the Welsh journey with integration tell us about the future for England?

Paul Mears (CEO, Cwm Taf Morgannwg University Health Board) joins Robert Hull (Senior Consultant – NHS Insight & Interaction, Mtech Access) to explore the integrated care model in Wales and the lessons England can take from the Welsh experience.

In this NHS Whispers webinar, guest speaker Paul Mears shares his experiences leading a Welsh health board. The 7 Health Boards in Wales have been operating as integrated systems for over a decade. With the NHS in England just getting to grips with integration, we explore what England can learn from the Welsh experience.

Robert and Paul explore:
 - How NHS Wales is structured and who the key decision makers are
 - How the integrated healthcare system works in Wales and how this differs to what’s happening in England
 - How priorities are set and what shapes decision-making at health board level
 - The nuances of the Welsh health system and what this means for industry
 - How Welsh Health Boards work with industry and the lessons here for ICBs and industry in England
 - Prudent healthcare and what this means in practice
 - How industry can best engage with health board leaders, what channels to use, and what messages to bring

This episode was first broadcast live as webinar in November 2023

Learn more about this webinar at: https://mtechaccess.co.uk/integrated-care-in-nhs-wales/.


Discover how we can help you with your NHS engagement and UK market access strategy at: https://mtechaccess.co.uk/uk-nhs-insights/

Subscribe to our newsletter to hear more news, insights and events from Petauri Evidence

Send us a text

Clare Foy (Director – Global Market Access, Mtech Access) speaks to Italian market access expert Prof. Fabrizio Gianfrate (Professor of Health Economics and Outcomes Research [HEOR] and Ex-Payer) about the market access landscape in Italy, particularly regarding changes at the Agenzia Italiana del Farmaco (AIFA).

We explore:
- The nature of the Italian market and the reimbursement process
- Pricing and market access considerations when launching in Italy
- What the reforms at AIFA mean for market access and managed entry agreements
- How the AIFA changes specifically impact innovative products
- Changes to early access programmes in Italy
- Impact of these changes on international pricing, particularly with the introduction of the EU Joint Clinical Assessment (JCA)

This episode was first broadcast as a live webinar in October 2023. Learn more at: https://mtechaccess.co.uk/italy-market-access-aifa-reforms/

Subscribe to our newsletter to hear more news, insights and events from Petauri Evidence